
    
      Treatment with sunitinib, 50 mg PO daily, 6 weeks courses with schedule 4/2 (4 weeks of
      treatment followed by 2 weeks of rest).

      Treatment until disease progression or unacceptable toxicity.

      Dose reduction depending on type and severity of toxicity. At the end of treatment period
      (after 8 courses), responding and well tolerating patients will be allowed to receive
      sunitinib upon investigator's opinion.

      Follow-up for up to 24 months from inclusion.
    
  